XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Current Assets    
Cash and cash equivalents (Note 6) $ 3,093.3 $ 3,268.4
Short-term investments (Note 6) 127.4 154.8
Accounts receivable, net of allowances of $15.5 (2025) and $14.9 (2024) 12,036.6 11,005.7
Other receivables 1,966.6 2,269.7
Inventories (Note 5) 9,311.0 7,589.2
Prepaid expenses 14,653.9 8,340.5
Other current assets 72.4 111.4
Total current assets 41,261.2 32,739.7
Investments (Note 6) 3,222.7 3,215.9
Goodwill 5,770.5 5,770.3
Other intangibles, net 6,012.2 6,166.3
Deferred tax assets 8,573.2 8,000.6
Property and equipment, net of accumulated depreciation of $12,146.9 (2025) and $11,789.0 (2024) 18,474.1 17,102.4
Other noncurrent assets 6,074.9 5,719.7
Total assets 89,388.8 78,714.9
Current Liabilities    
Short-term borrowings and current maturities of long-term debt 4,016.4 5,117.1
Accounts payable 3,442.0 3,228.6
Employee compensation 1,113.9 2,093.9
Sales rebates and discounts 11,550.3 11,539.3
Dividends payable 0.0 1,346.3
Short-term income taxes payable 6,175.7 1,116.4
Other current liabilities 3,769.8 3,935.0
Total current liabilities 30,068.1 28,376.6
Noncurrent Liabilities    
Long-term debt 34,499.5 28,527.1
Accrued retirement benefits (Note 8) 1,315.5 1,300.5
Long-term income taxes payable 5,370.5 4,060.9
Other noncurrent liabilities 2,288.4 2,178.2
Total noncurrent liabilities 43,473.9 36,066.7
Commitments and Contingencies (Note 9)
Eli Lilly and Company Shareholders' Equity    
Common stock 592.6 592.4
Additional paid-in capital 6,910.0 7,439.3
Retained earnings 15,099.5 13,545.0
Employee benefit trust (3,013.2) (3,013.2)
Accumulated other comprehensive loss (Note 10) (3,774.6) (4,321.9)
Cost of common stock in treasury (49.5) (49.5)
Total Eli Lilly and Company shareholders' equity 15,764.8 14,192.1
Noncontrolling interests 82.0 79.5
Total equity 15,846.8 14,271.6
Total liabilities and equity $ 89,388.8 $ 78,714.9